Barclays PLC Insmed Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Insmed Inc stock. As of the latest transaction made, Barclays PLC holds 332,063 shares of INSM stock, worth $25.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

332,063

Previous 332,063 -0.0%

Holding current value

$25.9 Million

Previous $24.2 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$62.0 - $79.01 $13.9 Million - $17.7 Million	223,468 Added 205.78%	332,063 $24.2 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $2.63 Million - $8.32 Million	-119,341 Reduced 52.36%	108,595 $7.28 Million
Q1 2024 May 15, 2024	SELL	$25.72 - $29.94 $2.74 Million - $3.19 Million	-106,593 Reduced 31.86%	227,936 $6.18 Million
Q4 2023 Feb 15, 2024	BUY	$23.42 - $31.74 $3.81 Million - $5.16 Million	162,728 Added 94.72%	334,529 $10.4 Million
Q3 2023 Nov 07, 2023	SELL	$19.86 - $26.93 $796,683 - $1.08 Million	-40,115 Reduced 18.93%	171,801 $4.34 Million
Q2 2023 Aug 03, 2023	SELL	$16.44 - $21.1 $11.9 Million - $15.3 Million	-725,024 Reduced 77.38%	211,916 $4.47 Million
Q1 2023 May 04, 2023	SELL	$16.26 - $21.73 $137,510 - $183,770	-8,457 Reduced 0.89%	936,940 $16 Million
Q4 2022 Feb 13, 2023	BUY	$16.98 - $23.15 $8.85 Million - $12.1 Million	521,346 Added 122.94%	945,397 $18.9 Million
Q3 2022 Nov 03, 2022	BUY	$20.88 - $28.21 $1.27 Million - $1.72 Million	60,979 Added 16.8%	424,051 $9.13 Million
Q2 2022 Aug 12, 2022	BUY	$17.07 - $25.71 $5.82 Million - $8.77 Million	341,164 Added 1557.26%	363,072 $7.16 Million
Q1 2022 May 16, 2022	SELL	$20.42 - $28.13 $2.48 Million - $3.42 Million	-121,447 Reduced 84.72%	21,908 $515,000
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $1.54 Million - $1.99 Million	59,564 Added 71.09%	143,355 $3.91 Million
Q3 2021 Nov 09, 2021	BUY	$22.46 - $29.47 $1.57 Million - $2.06 Million	70,029 Added 508.86%	83,791 $2.31 Million
Q2 2021 Aug 13, 2021	SELL	$24.17 - $36.01 $3.34 Million - $4.97 Million	-138,015 Reduced 90.93%	13,762 $392,000
Q1 2021 May 13, 2021	BUY	$32.28 - $44.3 $683,851 - $938,495	21,185 Added 16.22%	151,777 $5.17 Million
Q4 2020 Feb 11, 2021	SELL	$31.45 - $40.54 $1.86 Million - $2.39 Million	-58,999 Reduced 31.12%	130,592 $4.35 Million
Q3 2020 Nov 12, 2020	BUY	$26.0 - $34.5 $733,174 - $972,865	28,199 Added 17.47%	189,591 $6.09 Million
Q2 2020 Aug 12, 2020	BUY	$14.11 - $29.42 $392,469 - $818,317	27,815 Added 20.82%	161,392 $4.45 Million
Q1 2020 May 13, 2020	SELL	$13.63 - $33.98 $4.51 Million - $11.3 Million	-331,163 Reduced 71.26%	133,577 $2.14 Million
Q4 2019 Feb 10, 2020	BUY	$16.12 - $24.98 $6.37 Million - $9.88 Million	395,409 Added 570.32%	464,740 $11.1 Million
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $187,723 - $312,427	12,119 Added 21.18%	69,331 $1.22 Million
Q2 2019 Aug 14, 2019	SELL	$23.0 - $32.19 $1.49 Million - $2.09 Million	-64,873 Reduced 53.14%	57,212 $1.47 Million
Q1 2019 May 15, 2019	BUY	$13.91 - $31.15 $1.63 Million - $3.65 Million	117,055 Added 2327.14%	122,085 $3.55 Million
Q4 2018 Feb 14, 2019	SELL	$11.6 - $18.7 $362,511 - $584,393	-31,251 Reduced 86.14%	5,030 $66,000
Q3 2018 Nov 14, 2018	BUY	$18.95 - $28.08 $119,290 - $176,763	6,295 Added 20.99%	36,281 $734,000
Q2 2018 Aug 14, 2018	SELL	$20.0 - $29.72 $193,580 - $287,659	-9,679 Reduced 24.4%	29,986 $709,000
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $266,873 - $405,908	12,304 Added 44.97%	39,665 $894,000
Q4 2017 Feb 14, 2018	SELL	$26.43 - $31.78 $1.76 Million - $2.12 Million	-66,743 Reduced 70.92%	27,361 $853,000
Q3 2017 Nov 14, 2017	BUY	$11.61 - $31.21 $1.09 Million - $2.94 Million	94,104	94,104 $2.94 Million

Others Institutions Holding INSM

# of Institutions

484

Shares Held

182M

Call Options Held

2.14M

Put Options Held

3.25M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.6B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account